nemera&rsquos next generation nasal spray, advancia®, is now in production with 45 million units&39 annual capacitynemera has invested more than 10 million euros in r&d and manufacturing to launch the only userindependent multidose nasal spray system on the market.so far, the drug product packaging for advancia® is approved in one european country.advancia® represents a major breakthrough in nasal drug delivery by providing patients with a userindependent system ideal for topical and systemic preserved drugs in a userfriendly package.patient noncompliance with therapy could result in ineffective treatment or,in the case of potent drugs, harmful effects in patients.the new userindependent nasal spray packaging advancia® guarantees a consistent dose and spray, irrespective of the manner in which the patient uses it.this userindependent device is able to deliver excellent dose consistency exceeding the most stringent regulatory requirements. moreover, with its anticlogging technology, the system ensures spray delivery even with formulations that tend to crystallize. as a result, patients are not required to cleanthe actuator after each use. the extended prime retention of up to several months offers a unique solution for drugs for which treatment needs are infrequent hence the patients do not have to reprime the pump to ensure full delivery of the dose after several weeks of nonuse this also limits drug waste no spray loss. all these features improve patient compliance.advancia® offers several major advantagesuserindependenceexcellent dose consistencylong prime retentionmechanical closing tip to prevent problems due to cloggingno metal part in contact with the formulationcompatible with fea 20mm crimpon neck finish bottles plastic or glassfind nemera on the web at www.nemera.netnemera is one of the world leaders in the design, development and manufacturing of drug delivery solutions. its expertise covers all five modes of delivery nasalbuccalauricular spray pumps, actuators, valves, etc., ophthalmic preservativefree multidose eyedroppers, pulmonary pmdi, mdi&rsquos, dpi&rsquos, dermal transdermal airless & atmospheric dispensers, and parenteral autoinjectors, pens, and safety devices.nemera provides solutions for the pharmaceutical industry, including standardinnovative products, the development of proprietary devices and contract manufacturing. the advancia® innovative project is cofinanced by the european union. europe is committed in normandy with the european regional development fund feder.
